A month has gone by since the last earnings report for GSK (GSK). Shares have added about 3.2% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

LONDON (Reuters) -Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to below $5 per dose by 2028, ...

GSK PLC closed 16.45% below its 52-week high of £16.79, which the company reached on September 9th.

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine for potential distribution in low- and middle-income countries.

A month has gone by since the last earnings report for GSK (GSK). Shares have added about 3.2% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up ...

A month has gone by since the last earnings report for GSK (GSK). Shares have added about 3.2% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to ...